AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 163 filers reported holding AGIOS PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 1.81 and the average weighting 0.1%.
Links
Filings
- All filings
- Annual reports (10-K)
- Quarterly reports (10-Q)
- Insider transactions
- Shareholder votes
- Significant ownership
- Events
EDGAR links
External links
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $33,562 | -67.4% | 1,356 | -62.6% | 0.00% | – |
| Q2 2023 | $102,802 | +18.7% | 3,630 | -3.7% | 0.00% | – |
| Q1 2023 | $86,620 | -18.2% | 3,771 | +0.1% | 0.00% | – |
| Q4 2022 | $105,834 | -10.3% | 3,769 | -9.2% | 0.00% | – |
| Q3 2022 | $118,000 | +34.1% | 4,153 | +4.0% | 0.00% | – |
| Q2 2022 | $88,000 | +877.8% | 3,993 | +1175.7% | 0.00% | – |
| Q1 2022 | $9,000 | -59.1% | 313 | -52.6% | 0.00% | – |
| Q4 2021 | $22,000 | -72.5% | 660 | -61.8% | 0.00% | – |
| Q3 2021 | $80,000 | -21.6% | 1,727 | -6.1% | 0.00% | – |
| Q2 2021 | $102,000 | +9.7% | 1,839 | +0.8% | 0.00% | – |
| Q1 2021 | $93,000 | -55.1% | 1,825 | -61.8% | 0.00% | – |
| Q4 2020 | $207,000 | +31.8% | 4,773 | +6.6% | 0.00% | – |
| Q3 2020 | $157,000 | +441.4% | 4,477 | +721.5% | 0.00% | – |
| Q2 2020 | $29,000 | +38.1% | 545 | -9.8% | 0.00% | – |
| Q1 2020 | $21,000 | -68.7% | 604 | -57.7% | 0.00% | – |
| Q4 2019 | $67,000 | +252.6% | 1,427 | +146.5% | 0.00% | – |
| Q3 2019 | $19,000 | -62.0% | 579 | -42.7% | 0.00% | – |
| Q2 2019 | $50,000 | +35.1% | 1,010 | +82.6% | 0.00% | – |
| Q1 2019 | $37,000 | +32.1% | 553 | -9.8% | 0.00% | – |
| Q4 2018 | $28,000 | -47.2% | 613 | -10.2% | 0.00% | – |
| Q3 2018 | $53,000 | -3.6% | 683 | +4.1% | 0.00% | – |
| Q2 2018 | $55,000 | +511.1% | 656 | +480.5% | 0.00% | – |
| Q1 2018 | $9,000 | +50.0% | 113 | 0.0% | 0.00% | – |
| Q4 2017 | $6,000 | -33.3% | 113 | -13.1% | 0.00% | – |
| Q3 2017 | $9,000 | +50.0% | 130 | +15.0% | 0.00% | – |
| Q2 2017 | $6,000 | -40.0% | 113 | -38.3% | 0.00% | – |
| Q1 2017 | $10,000 | +100.0% | 183 | +61.9% | 0.00% | – |
| Q4 2016 | $5,000 | -16.7% | 113 | 0.0% | 0.00% | – |
| Q3 2016 | $6,000 | -72.7% | 113 | -79.0% | 0.00% | – |
| Q2 2016 | $22,000 | +22.2% | 538 | +24.8% | 0.00% | – |
| Q1 2016 | $18,000 | -28.0% | 431 | +18.1% | 0.00% | – |
| Q3 2015 | $25,000 | -41.9% | 365 | -7.1% | 0.00% | – |
| Q2 2015 | $43,000 | +13.2% | 393 | -3.0% | 0.00% | – |
| Q1 2015 | $38,000 | +660.0% | 405 | +726.5% | 0.00% | – |
| Q4 2014 | $5,000 | – | 49 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Eagle Health Investments LP | 431,413 | $12,558,000 | 3.09% |
| Casdin Capital, LLC | 2,090,000 | $60,840,000 | 2.73% |
| Rock Springs Capital Management LP | 2,665,275 | $77,586,000 | 1.95% |
| Bellevue Group AG | 4,129,292 | $120,204,000 | 1.40% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,177,374 | $34,273,000 | 1.05% |
| Altium Capital Management LP | 66,196 | $1,927,000 | 0.64% |
| ArrowMark Colorado Holdings LLC | 1,295,948 | $37,725,000 | 0.33% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,333,012 | $38,804,000 | 0.19% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 21,500 | $707,000 | 0.16% |
| Virtus ETF Advisers LLC | 11,541 | $336,000 | 0.15% |